Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BioLineRx
|
2024 | |||
BioLineRx BLRX Q1 2024 |
BioLineRx BLRX Q2 2024 |
||
May 28, 2024 | Aug. 15, 2024 | ||
2023 | |||
BioLineRx BLRX Q3 2023 |
BioLineRx BLRX Q4 2023 |
||
Nov. 20, 2023 | Mar. 26, 2024 |
Biolinerx (BLRX) is a recently commercial stage biotechnology company specializing in therapies for stem cell mobilization to combine with cancer therapies.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BMY |
BLUE |
CLDX |
CDTX |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
TSVT |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers